Completed Preclinical (in vivo) 2024

    Novel pan-ERR agonists ameliorate heart failure through enhancing cardiac fatty acid metabolism and mitochondrial function

    Xu W, Billon C, Li H, et al.

    Circulation

    DOI: 10.1161/CIRCULATIONAHA.123.066542

    Summary

    Showed that SLU-PP-332 and its successor SLU-PP-915 significantly improved cardiac ejection fraction, reduced fibrosis, and increased survival in pressure overload-induced heart failure. The ERR-gamma-mediated cardioprotection occurs through enhanced fatty acid metabolism and mitochondrial oxidative capacity.

    Key Findings

    • SLU-PP-332 improved ejection fraction and increased survival in heart failure model
    • Normalized fatty acid and mitochondrial metabolic profiles in failing hearts
    • ERR-gamma identified as the main mediator of cardioprotective transcriptional regulation

    Access Full Text

    Read the complete published study from the original source.

    View on Publisher Site

    Related Monographs

    Related Studies

    View all →
    Completed 2024

    A synthetic ERR agonist alleviates metabolic syndrome

    Billon C, Schoepke E, Avdagic A, et al.

    Journal of Pharmacology and Experimental Therapeutics

    Demonstrated that SLU-PP-332 mimics exercise-induced metabolic benefits in obese mice, including increased energy expenditure, enhanced fatty acid oxidation, decreased fat mass accumulation, and improved insulin sensitivity. Establishes ERR agonism as a viable approach to treat metabolic syndrome.

    • SLU-PP-332 increased energy expenditure and fatty acid oxidation in diet-induced obese mice
    • Significantly decreased fat mass accumulation without changes in food intake

    DOI: 10.1124/jpet.123.001782

    Completed 2023

    Synthetic ERR alpha/beta/gamma agonist induces an ERR-alpha-dependent acute aerobic exercise response and enhances exercise capacity

    Billon C, Sitaula S, Banerjee S, et al.

    ACS Chemical Biology

    First characterization of SLU-PP-332 as a pan-ERR agonist with highest potency for ERR-alpha. Administration to mice increased type IIa oxidative skeletal muscle fibers, enhanced exercise endurance, and activated an acute aerobic exercise genetic program — establishing it as a pharmacological exercise mimetic.

    • SLU-PP-332 is a first-in-class pan-ERR agonist targeting all three ERR subtypes
    • Increased type IIa oxidative muscle fibers and enhanced exercise endurance in mice

    DOI: 10.1021/acschembio.2c00720